Such finding could provide insights into new drug targets for rectal cancer similar to the inhibition of NF-κB dependent intestinal inflammation attained by targeting an enteroglial-specific protein/TLR4 axis that demonstrated therapeutic effects in ulcerative colitis [71]. Here, NFKB1 is linked to rectal cancer.